The biology is too complicated. Pharma companies are quitting. Where are schizophrenia drugs going to come from?
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lieberman, J. A. et al. N. Engl. J. Med. 353, 1209-1223 (2005).
Buchanan, R. W. et al. Schizophr. Bull. 31, 5-19 (2005).
Kirkpatrick, B., Fenton, W. S., Carpenter, W. T. Jr & Marder, S. R. Schizophr. Bull. 32, 214-219 (2006).
Steffanson, H. et al. Nature 455, 232-236 (2008).
Related links
Related links
Related links in Nature Research
Neuropsychiatric disease Insight
Related external links
Rights and permissions
About this article
Cite this article
Abbott, A. Schizophrenia: The drug deadlock. Nature 468, 158–159 (2010). https://doi.org/10.1038/468158a
Published:
Issue Date:
DOI: https://doi.org/10.1038/468158a